Key result
Trastuzumab-associated dilated cardiomyopathy resolves following drug discontinuation and standard medical therapy.
Why the study?
Cardiotoxicity manifesting as dilated cardiomyopathy is a rarely reported adverse effect of trastuzumab chemotherapy.
Case Report (n=1)
Trastuzumab chemotherapy can cause dilated cardiomyopathy, which may be reversible upon discontinuation and standard medical treatment.
Answers are grounded in this paper and cite their sources.
Trastuzumab may induce reversible cardiomyopathy; single case leaves open incidence and monitoring guidance.
The war against cancer has seen a proliferation in armamentarium over the last decades. A new antineoplastic agent, trastuzumab, was synthesized in 1991 and gained United States Food and Drug Administration approval in 1998 for treatment of metastatic breast cancer. Cardiotoxicity manifesting as dilated cardiomyopathy is a rarely reported adverse effect of trastuzumab. We hereby report a case of dilated cardiomyopathy, which occurred following trastuzumab chemotherapy in a 32-year-old female. The patient responded to discontinuation of trastuzumab and standard medical treatment. Extensive search of Indian literature revealed no reported case of dilated cardiomyopathy occurring due to trastuzumab.
No takes yet. Share an insight, caveat, or question.
Karmakar et al. (2012) conducted a case report in Metastatic breast cancer (n=1). Trastuzumab was evaluated on Dilated cardiomyopathy. Trastuzumab chemotherapy was associated with the development of dilated cardiomyopathy in a 32-year-old female, which resolved upon discontinuation of the drug and standard medical treatment.
Synapse has enriched 10 related papers. Consider them for comparative context: